There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA – Research Report) and Tenaya Therapeutics (TNYA – Research Report) with bullish sentiments.
Inventiva (IVA)
Canaccord Genuity analyst Edward Nash maintained a Buy rating on Inventiva today and set a price target of $12.00. The company’s shares closed last Monday at $4.36.
According to TipRanks.com, Nash is a 3-star analyst with an average return of
Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $18.25, implying a 333.5% upside from current levels. In a report issued on March 7, LifeSci Capital also maintained a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
Tenaya Therapeutics (TNYA)
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target of $19.00. The company’s shares closed last Monday at $4.82.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
Tenaya Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.67, which is a 197.6% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IVA:
